@misc{10481/57838,
year = {2018},
month = {8},
url = {http://hdl.handle.net/10481/57838},
abstract = {The aim of this study was to evaluate the effect of sitagliptin on glucose tolerance, plasma lipids, energy
expenditure and metabolism of brown adipose tissue (BAT), white adipose tissue (WAT) and skeletal muscle in overweight
individuals with prediabetes (impaired glucose tolerance and/or impaired fasting glucose). One participant from the sitagliptin group was excluded from analysis, due to a distribution error, leaving 29 participants
for further analysis. Sitagliptin, but not placebo, lowered glucose excursion (−40%; p < 0.003) during OGTT, accompanied by an
improved insulinogenic index (+38%; p < 0.003) and oral disposition index (+44%; p < 0.003). In addition, sitagliptin lowered
serum concentrations of triacylglycerol (−29%) and very large (−46%), large (−35%) and medium-sized (−24%) VLDL particles
(all p < 0.05). Body weight, body composition and energy expenditure did not change. In skeletal muscle, sitagliptin increased mRNA expression of PGC1β (also known as PPARGC1B) (+117%; p < 0.05), a main controller of mitochondrial oxidative
energy metabolism. Although the primary endpoint of change in BAT volume and activity was not met, sitagliptin increased [18F]
FDG uptake in subcutaneous WAT (sWAT; +53%; p < 0.05). Reported side effects were mild and transient and not necessarily
related to the treatment. Twelve weeks of sitagliptin in overweight, Europid men with prediabetes improves glucose tolerance
and lipid metabolism, as related to increased [18F] FDG uptake by sWAT, rather than BAT, and upregulation of the mitochondrial
gene PGC1β in skeletal muscle. Studies on the effect of sitagliptin on preventing or delaying the progression of prediabetes into
type 2 diabetes are warranted.},
organization = {This work was supported in part by a research grant to PCNR
fromthe Investigator Initiated Studies Programof Merck Sharp&Dohme
Corp (IIS no. 51292). PCNR is an Established Investigator of the Dutch
Heart Foundation (grant 2009T038). MRB is supported by a Dutch
Diabetes Research Foundation Fellowship (grant 2015.81.1808). This
collaboration project is also supported in part by the Ministry of
Economic Affairs by means of the PPP Allowance made available by
the Top Sector Life Sciences & Health to stimulate public–private partnerships.
BMT and JRR are supported by University of Granada, Plan
Propio de Investigacion 2016, Excellence actions: Units of Excellence;
Unit of Excellence on Exercise and Health (UCEES). This work was also
supported by the Netherlands CardioVascular Research Initiative: ‘the
Dutch Heart Foundation, Dutch Federation of University Medical
Centers, the Netherlands Organisation for Health Research and
Development and the Royal Netherlands Academy of Sciences’ for the
GENIUS-II project ‘Generating the best evidence-based pharmaceutical
targets for atherosclerosis’ (CVON2017-20).},
publisher = {Springer Nature},
keywords = {Brown adipose tissue},
keywords = {DPP4 inhibitor},
keywords = {Energy expenditure},
keywords = {Skeletal muscle},
keywords = {Diabetes risk},
keywords = {Dyslipidaemia},
keywords = {Obesity},
title = {Effect of sitagliptin on energy metabolism and brown adipose tissue in overweight individuals with prediabetes: a randomised placebo-controlled trial},
doi = {10.1007/s00125-018-4716-x},
author = {Nahon, Kimberly J. and Martínez Téllez, Borja Manuel and Ruiz Ruiz, Jonatan},
}